Pirfenidone treatment in idiopathic pulmonary fibrosis: Too much of a great expectation?

European Respiratory Journal

Volumn 40, Issue 3, 2012, Pages 794-795

  Papiris, Spyros A ^a   Kagouridis, Konstantinos ^a   Kolilekas, Likourgos ^a   Triantafillidou, Christina ^b   Tsangaris, Iraklis ^a   Manali, Effrosyni D ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PIRFENIDONE; PLACEBO; PREDNISONE;

DISEASE ASSOCIATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; SURVIVAL TIME; TREATMENT INDICATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; PYRIDONES; RESPIRATORY FUNCTION TESTS;

EID: 84863870796     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00114311     Document Type: Letter

References (11)

1. Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010; 9: 129-140.
3. Papiris SA, Manali ED, Kolilekas L, et al. Clinical review: idiopathic pulmonary fibrosis acute exacerbations - unravelling Ariadne's thread. Crit Care 2010; 14: 246.
4. National Heart, Lung, and Blood Institute. NIH News. Commonly used three-drug regimen for idiopathic pulmonary fibrosis found harmful. October 21, 2011. www.nih.gov/news/health/oct2011/nhlbi-21.htm Date last accessed: January 22, 2012.
5. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-1047. (Pubitemid 40616955)
6. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
7. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
8. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-542. (Pubitemid 37088595)
9. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-1389.
10. Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77: 371-383. (Pubitemid 34260746)
11. Man-Son-Hing M, Laupacis A, O'Rourke K, et al. Determination of the clinical importance of study results. J Gen Intern Med 2002; 17: 469-476. (Pubitemid 34989015)